Trial · NCT00878709
Results by group42
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 42
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 | Neratinib | 4.7 | percentage of participants with events | ||
| Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 | Placebo | 7.5 | percentage of participants with events | ||
| Kaplan-Meier Estimates of Invasive Disease-free Survival (iDFS) at Year 2 by Treatment Arms | Neratinib | 94.2 | 95% Confidence Interval 92.6 to 95.4 | percentage of participants | |
| Kaplan-Meier Estimates of Invasive Disease-free Survival (iDFS) at Year 2 by Treatment Arms | Placebo | 91.9 | 95% Confidence Interval 90.2 to 93.2 | percentage of participants | |
| Overall Survival (OS) | Neratinib | 1 Year Kaplan-Meier Estimate | 99.64 | 95% Confidence Interval 99.13 to 99.85 | percentage of participants |
| Overall Survival (OS) | Placebo | 1 Year Kaplan-Meier Estimate | 99.43 | 95% Confidence Interval 98.86 to 99.71 | percentage of participants |
| Overall Survival (OS) | Neratinib | 3 Year Kaplan-Meier Estimate | 96.74 | 95% Confidence Interval 95.62 to 97.57 | percentage of participants |
| Overall Survival (OS) | Placebo | 3 Year Kaplan-Meier Estimate | 96.44 | 95% Confidence Interval 95.30 to 97.31 | percentage of participants |
| Overall Survival (OS) | Neratinib | 5 Year Kaplan-Meier Estimate | 94.09 | 95% Confidence Interval 92.65 to 95.25 | percentage of participants |
| Overall Survival (OS) | Placebo | 5 Year Kaplan-Meier Estimate | 93.26 | 95% Confidence Interval 91.77 to 94.49 | percentage of participants |
| Overall Survival (OS) | Neratinib | 7 Year Kaplan-Meier Estimate | 91.36 | 95% Confidence Interval 89.66 to 92.79 | percentage of participants |
| Overall Survival (OS) | Placebo | 7 Year Kaplan-Meier Estimate | 91.29 | 95% Confidence Interval 89.62 to 92.70 | percentage of participants |
| Overall Survival (OS) | Neratinib | 9 Year Kaplan-Meier Estimate | 89.06 | 95% Confidence Interval 86.97 to 90.84 | percentage of participants |
| Overall Survival (OS) | Placebo | 9 Year Kaplan-Meier Estimate | 88.65 | 95% Confidence Interval 88.58 to 90.43 | percentage of participants |
| Disease-free Survival Including Ductal Carcinoma in Situ (DFS-DCIS) in Neratinib Arm Compared to Placebo Arm at Year 2 | Neratinib | 4.7 | percentage of participants with events | ||
| Disease-free Survival Including Ductal Carcinoma in Situ (DFS-DCIS) in Neratinib Arm Compared to Placebo Arm at Year 2 | Placebo | 8.0 | percentage of participants with events | ||
| Kaplan-Meier Estimates of Disease-free Survival Including Ductal Carcinoma in Situ (DFS-DCIS) at Year 2 by Treatment Arms | Neratinib | 94.2 | 95% Confidence Interval 92.6 to 95.4 | percentage of participants | |
| Kaplan-Meier Estimates of Disease-free Survival Including Ductal Carcinoma in Situ (DFS-DCIS) at Year 2 by Treatment Arms | Placebo | 91.3 | 95% Confidence Interval 89.6 to 92.7 | percentage of participants | |
| Distant Disease-free Survival (DDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 | Neratinib | 3.8 | percentage of participants with events | ||
| Distant Disease-free Survival (DDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 | Placebo | 5.4 | percentage of participants with events |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00878709/results